Antibody-hyaluronic acid bioconjugates for localized treatment of chronic non-infectious uveitis

Valitor, Inc., Berkeley CA

Investigators

Abstract

Project Summary Uveitis is a group of diseases characterized by sight-threatening intraocular inflammation and responsible for roughly 5-10% of blindness cases worldwide. Uveitis flare-ups can be caused by either an active infection or, in in the case of non-infectious uveitis (NIU), a dysregulated immune response including altered cytokine expression and processing. Thus, there is an urgent and unmet need for more effective treatments. The standard first line therapies for chronic NIU are corticosteroids delivered either topically, systemically, or locally through intravitreal injections or implants. However, long-term use of these treatments is associated with serious side effects. Alternative anti-inflammatory therapeutics are often used to minimize these side-effects and inhibition of the pro-inflammatory cytokine, TNF? has become a key approach. Systemic delivery of TNF? inhibitors is effective but costly and carries a risk of side-effects from long-term use. Valitor, Inc. is developing protein-polymer therapeutics to overcome the vision-threatening effects of chronic ocular inflammation with substantially fewer systemic side effects by enabling intravitreal delivery of a biologic anti-TNF? therapy. We have conjugated single-domain anti-TNF? antibodies (VHH) to linear chains of the natural biopolymer hyaluronic acid to generate multivalent anti-TNF? conjugates (Anti-TNF? MVP) that are substantially larger than any other drugs currently delivered by intravitreal injection. In our previous studies, we verified that the large sizes of our MVPs are sufficient to substantially reduce their clearance rate out of the vitreous, thereby providing a sustained treatment effect to inhibit intraocular TNF?. Thus, our strategy for sustained anti-TNF? therapy has the potential to improve the long-term efficacy, safety, and cost efficacy of anti-TNF? treatment. The overall objective of this Phase I SBIR project is to verify that our Anti-TNF? MVPs exhibit a rapid onset and durable anti-inflammatory treatment for chronic non-infections uveitis. In Specific Aim #1, we will evaluate the ability of an Anti-TNF? MVP to generate a rapid anti-inflammatory response compared to that of a corticosteroid. In Specific Aim #2, we will verify the anti-inflammatory durability of our Anti-TNF? MVP to that of a clinically available TNF? inhibitor. The results of this project will be used to continue the development of our Anti-TNF? MVP drug product and contribute to a productive pre-IND meeting to confirm the additional testing that required for our IND submission.